Abstracts patients were initiated on 25mg of RLAI. At 12-months 63% of patients were still on RLAI. The reasons for discontinuation were lack of response (14%); loss-to-follow-up (10.5%); other (7.5%); patient or family choice (6%); adverse events (6%); tolerability (2%); and adherence (1.5%). Young age at schizophrenia onset and suicidal behavior at baseline were significant risk factors for time to discontinuation (p < 0.04).
PMH5 INCIDENT DIABETES ASSOCIATED WITH USE OF SECOND-GENERATION ANTIPSYCHOTIC (SGA) THERAPY: AN EVALUATION OF THE IMPACT OF DOSE AND TREATMENT INDICATION
University of Texas at Austin, Austin, TX, USA, 2 South Texas Veterans Health Care System, San Antonio, TX, USA OBJECTIVE: While SGA therapy has been associated with newonset diabetes, the relative risk of the agents and the impact of possible confounding variables have been questioned. This study evaluated the impact of dose and treatment indication on the relative risk of new-onset diabetes associated with SGA therapy while controlling for demographic, clinical and medication variables. METHODS: A retrospective database analysis capturing electronic medical records for adult Texas Medicaid enrollees taking antipsychotic monotherapy from January 1997 to December 2001, with a maximum follow-up of 12 months was used. Patients were stratified according to treatment dose (low, medium, high) and a hierarchy of mutually exclusive diagnostic categories: schizophrenia, bipolar disorder, dementia, psychotic disorder, non-psychotic disorder and no mental health indication. The incidence of diabetes was examined using multivariate logistic regression analysis. RESULTS: Data were available for 13,731 patients. At treatment-onset, the prevalence of diabetes was 16.9%. The mean (SD) dose by indication for the most prevalent conditions (schizophrenia, bipolar disorder and dementia, respectively) were as follows: olanzapine (12.04mg (6.73); 8.91mg (5.78); 4.87mg (3.00)); quetiapine (273.16mg (203.86); 146.33mg (142.29) ; 79.59 (82.57)); and risperidone (3.55mg (2.37); 2.05 (1.76); 1.12 (0.85)). The overall incidence of diabetes was 2.6%. Multivariate logistic regression analysis showed no difference in the incidence of diabetes according to the agent used (p = 0.281). Compared to risperidone, the odds of new-onset diabetes were 0.879 (95% CI: 0.653 to 1.184) and 0.683 (95% CI: 0.414 to 1.126) for olanzapine and quetiapine, respectively. Neither treatment indication (p = 0.876) nor antipsychotic dose (p = 0.274) were associated with the development of diabetes. CONCLUSIONS: Results indicate that the risk of new-onset diabetes does not differ among SGA agents (i.e., olanzapine, quetiapine and risperidone). While the dose of antipsychotic prescribed varied significantly according to treatment indication and patient age, neither dose nor indication were associated with the development of diabetes. Atypical antipsychotic-induced diabetes has raised concerns recently, while the extent of atypical antipsychotic-induced diabetes mellitus among Asians with schizophrenia is not well known. This study aims to compare the association of atypical antipsychotic treatments and diabetes mellitus with that of haloperidol treatment and diabetes mellitus among schizophrenic patients in Taiwan. METHODS: Data used in this study came from Taiwan's National Health Insurance claims database for the period 2000-2004. This study identified antipsychotic treatment episodes of clozapine, olanzapine, risperidone, quetiapine, amisulpride, ziprasidone, and haloperi-dol. Inclusion criteria of treatment episodes were that the subjects were aged 18 years or above, had had at least one admission due to schizophrenia during the two-year period prior to the initiation of the treatment episodes, and with no diabetes mellitus during a one-year period prior to the initiation of the treatment episodes. Diabetes mellitus was identified by claims with such diagnosis or with antidiabetic agents. A logistic regression model was applied to evaluate the likelihood of newly-onset cases of diabetes of different antipsychotic treatment episodes. Patient and clinical characteristics were included as covariates. RESULTS: Compared with users of haloperidol, those receiving clozapine, olanzapine, and risperidone had a higher probability of developing diabetes mellitus. Those taking quetiapine, amisulpride, and ziprasidone, however, had no significantly higher odds of developing diabetes mellitus. CONCLUSIONS: The preliminary findings of this study support reports of atypical antipsychotics-induced diabetes mellitus. Clozapine, olanzapine, and risperidone, compared with haloperidol, are associated with an increased risk of diabetes mellitus among schizophrenic patients in Taiwan. We examined 1999-2003 data from a claims database of 1.2 million beneficiaries, from 7 large U.S. employers. Analysis was restricted to employees aged 18-64, with at least one diagnosis of major depressive disorder (ICD-9: 296.2x, 296.3x) and at least one prescription of selective serotonin or seratonin/norepinephrine reuptake inhibitor (SSRI/SNRI). Patients were classified as combination antidepressant therapy users, switchers, discontinuers, or monotherapy maintainers. Annual direct health care costs, including drug and medical costs (comprising inpatient, outpatient, and emergency visits), and indirect work loss costs (comprising absenteeism and disability) were calculated for the 12-month period following therapy initiation. Results were compared descriptively across treatment responses using t-tests and ANOVA analyses. RESULTS: Of the 3971 patients, 18.4% were on combination therapy, 19.7% switchers, 45.1% discontinuers, and 16.8% monotherapy maintainers. Patients on combination therapy had similar direct and indirect costs compared to switchers (all p >= 0.08). The average direct and indirect costs for patients on combination therapy and switchers ($7986 and $2806 respectively) were higher than those for discontinuers ($6013 and $1680 respectively, all p < 0.001) or maintainers ($5193 and $1467 respectively, all p < 0.001). Compared to patients on combination therapy and switchers, maintainers had similar drug costs ($1980 vs. $2068, p = 0.469) . Compared to discontinuers, maintainers had higher drug costs ($1,980 vs. $1095, p < 0.001), but lower medical ($3214 vs. $4918, p = 0.002) and disability costs ($360 vs. $664, p = 0.008). CONCLUSION: Patients on combination therapy or who switched monotherapy had higher average direct health care costs and indirect work loss costs than patients who discontinued or maintained therapy. Maintainers had higher drug costs but lower medical and disability costs compared to discontinuers. 
PMH6 NEW-ONSET DIABETES MELLITUS ASSOCIATED WITH USE OF ATYPICAL ANTIPSYCHOTICS AMONG SCHIZOPHRENIC PATIENTS IN TAIWAN

MENTAL HEALTH-Cost
PMH8 COST-EFFECTIVENESS OF VENLAFAXINE: A CANADIAN PERSPECTIVE
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METHODS:
The model estimated the cost-effectiveness (CE) ratios for each AAP when used as monotherapy for the acute (3-week) treatment of patients with bipolar mania. CE ratios were defined as the total annual cost per responder, and responders were defined as patients with a 50% improvement on the YMRS scale at 3 weeks. Data sources included published literature, package inserts, and primary data analysis of a managed care claims database. The median response rate for each AAP was used in the base case scenario; 45.5%, 50.0%, 58.0%, 53.3%, and 56.7% for aripiprazole, ziprasidone, risperidone, quetiapine, and olanzapine, respectively. Since there are no pub-
